Core Viewpoint - SaiLu Medical has completed A+ round financing led by Fosun Pharma, with funds aimed at upgrading domestic sequencing platforms and expanding market presence, driving innovation in life science tools [1][2]. Group 1: Financing and Investment - The A+ round financing was led by Fosun Pharma, with participation from Weichi Investment and existing shareholder Shenzhen Capital Group [2]. - The funds will be primarily used for the registration and declaration of domestic sequencing platforms, capacity expansion, and global market development [2][3]. Group 2: Company Development and Achievements - Since its establishment in 2020, SaiLu Medical has maintained rapid development, achieving significant milestones such as obtaining the NMPA Class III medical device registration for its Salus Pro sequencer in January 2025 [2]. - The company has built a comprehensive R&D system covering optics, fluidics, chips, and reagents, and has accumulated over 100 authorized patents [3]. Group 3: Strategic Collaboration - The financing marks a new phase of strategic cooperation between Fosun Pharma and SaiLu Medical, focusing on product development, resource integration, and global market expansion [6]. - Both companies will emphasize "innovation-driven" strategies to accelerate the development of innovative technologies and products that meet clinical needs [6].